Moxifloxacin for the treatment of patients with complicated intra-abdominal infections (the AIDA study)

Journal of Chemotherapy

Volumn 21, Issue 2, 2009, Pages 170-180

  Weiss, G ^a   Reimnitz, P ^b   Hampel, B ^c   Muehlhofer, E ^b   Lippert, H ^a  

^a UNIVERSITY HOSPITAL MAGDEBURG   (Germany)

^b BAYER AG   (Germany)

^c BAYER PHARMA AG   (Germany)

Author keywords

Amoxicillin clavulanate; Ceftriaxone; Complicated intra abdominal infection; Metronidazole; Moxifloxacin

Indexed keywords

AMOXICILLIN PLUS CLAVULANIC ACID; CEFTRIAXONE; METRONIDAZOLE; MOXIFLOXACIN;

ABDOMINAL INFECTION; ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; APPENDIX; ARTICLE; CLINICAL TRIAL; COLON; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DRUG WITHDRAWAL; DUODENUM; FEMALE; GALLBLADDER; HUMAN; ILEUM; INFECTION; INFESTATION; MAJOR CLINICAL STUDY; MALE; MONOTHERAPY; MULTICENTER STUDY; NAUSEA; OPEN STUDY; PHASE 3 CLINICAL TRIAL; PROSPECTIVE STUDY; QT PROLONGATION; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; STOMACH;

EID: 67249152506     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.2009.21.2.170     Document Type: Article

References (29)

1. Berger D, Buttenschoen K. Management of abdominal sepsis. Langenbecks Arch Surg 1998; 383: 35-43.
2. Bruch HP, Woltmann A, Eckmann C. Surgical management of peritonitis and sepsis. Zentralbl Chir 1999; 124: 176-180.
3. Buijk SE, Bruining HA. Future directions in the management of tertiary peritonitis. Intensive Care Med 2002; 28: 1024-1029.
4. Marshall JC, Innes M. Intensive care unit management of intra-abdominal infection. Crit Care Med 2003; 31: 2228-2237.
5. Roehrborn A, Thomas L, Potreck O, Ebener C, Ohmann C, Goretzki PE, et al. The microbiology of postoperative peritonitis. Clin Infect Dis 2001; 33: 1513-1519.
6. Blot S, De Waele JJ. Critical issues in the clinical management of complicated intra-abdominal infections. Drugs 2005; 65: 1611-1620.
7. Stass H, Rink AD, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and peritoneal penetration of moxifloxacin in peritonitis. J Antimicrob Chemother. 2006; 58: 693-696.
8. Rink AD, Stass H, Delesen H, Kubitza D, Vestweber KH. Pharmacokinetics and tissue penetration of moxifloxacin in intervention therapy for intra-abdominal abscess. Clin Drug Invest 2008; 28: 71-79.
9. Solomkin JS, Mazuski JE, Baron EJ, Sawyer RG, Nathens AB, DiPiro JT, et al. Guidelines for the selection of anti-infective agents for complicated intra-abdominal infections. Clin Infect Dis 2003; 37: 997-1005.
10. AVELOX® tablets UK prescribing information, Bayer Schering Pharma, November 2007.
11. Ackermann G, Schaumann R, Pless B, Claros MC, Goldstein EJC, Rodloff AC. Comparative activity of moxifloxacin in vitro against obligate anaerobic bacteria. Eur J Clin Microbiol Infect Dis 2000; 19: 228-232.
12. Edmiston CE, Krepel CJ, Seabrook GR, Somberg LR, Na-keeb A, Cambria RA, et al. In vitro activities of moxifloxacin against 900 aerobic and anaerobic surgical isolates from patients with intra-abdominal and diabetic foot infections. Antimicrob Agents Chemother 2004; 48: 1012-1016.
13. Muller M, Stass H, Brunner M, Moller JG, Lackner E, Eichler HG. Penetration of moxifloxacin into peripheral compartments in humans. Antimicrob Agents Chemother 1999; 43: 2345-2349.
14. Wirtz M, Kleeff J, Swoboda S, Halaceli I, Geiss HK, Hoppe-Tichy T, et al. Moxifloxacin penetration into human gastrointestinal tissues. J Antimicrob Chemother 2004; 53: 875-877.
15. Mayer-Bartschmid A, Schuhmacher J, Dorlemann S, Haas A. Determination of PK/PD parameters of moxifloxacin against Bacteroides thetaiotaomicron in vitro at static and at varying drug concentrations. 17th European Congress of Clinical Micro-biology and Infectious Diseases and 25th International Congress of Chemotherapy, Munich, Germany, 31 March-3 April 2007. poster 1651.
16. Glenschek-Sieberth M, MerfortK, Obertegger S, Knezevic I, Endermann R. In vivo efficacy of moxifloxacin monotherapy against clinical isolates of B. fragihs with intermediate susceptibility. European Congress of Clinical Microbiology and Infectious Diseases, Barcelona, Spain, 19-22 April 2008, poster 1065.
17. Glenschek-Sieberth M, Merfort K, Obertegger S. A new animal model for severe complications of intra-abdominal infections: chronic uterus infections caused by B. fragilis. European Congress of Clinical Microbiology and Infectious Diseases. Barcelona, Spain, 19-22 April 2008, poster 1932.
18. Thadepalli H, Chuah SK, Gollapudi S. Therapeutic efficacy of moxifloxacin, a new quinolone, in the treatment of experimental intra-abdominal abscesses induced by Bacteroides fragilis in mice. Chemotherapy 2004; 50: 76-80.
19. Glenschek-Sieberth M, Mayer-Bartschmid A. Merfort K, Obertegger S, Hartke S, Haas M. In vivo and in vitro efficacy of moxifloxacin monotherapy against B. fragilis mutant strains with elevated MICs. 47th Annual Interscience Conference on Antimicrobial Agents and Chemotherapy, 17-20 September 2007. Chicago, USA, poster A-21.
20. Malangoni MA, Song J, Herrington J, Choudhri S. Pertel P. Randomized controlled trial of moxifloxacin compared with piperacillin-tazobactam and amoxicillin-clavulanate for the treatment of complicated intra-abdominal infections. Ann Surg 2006: 244: 20-11.
21. lSolomkin JS, Zhao Y-P, Chen M-J, et al. Moxifloxacin IV is an effective empirical therapy for complicated intra-abdominal infections (cIAIs) - the DRAGON study. 16th Asian Surgical Biennial Congress. 19-22 October 2007, Beijing, China.
22. Lippert H, Weiss G, Choudhri SH, Herrington J, Briel-mann J-M. Clinical and bacteriological efficacy of sequential intravenous (IV) to oral (PO) moxifloxacin in patients with complicated intra-abdominal Infections (cIAI) due to Enterobac-teriaceae. 20th European Congress on Surgical Infections, Frankfurt, Germany, 17-19 May 2007.
23. Lippert H, Weiss G, Malangoni M. et al. Bacteriological efficacy of sequential intravenous (IV) to oral (PO) moxifloxacin for polymicrobial complicated intra-abdominal infections (cIAI). 20th European Congress on Surgical Infections, Frankfurt. Germany. 17-19 May 2007, abstract.
24. Avelox IV US Prescribing Information. Bayer HealthCare and Schering-Plough, 2007.
25. Cisneros RL, Onderkonk AB. Antimicrobial efficacy testing of moxifloxacin during the peritonitis and abscess formation stages of intra-abdominal sepsis: a controlled trial in the rat model. Curr Ther Res Clin Exp 2002; 63: 821-827.
26. Barie P, Vogel ST, Dellinger E, Rotstein O, Solomkin JS. Yang JY, et al. A randomized, double-blind clinical trial comparing cefipime plus metronidazole with imipenem-cilastatin in the treatment of complicated intraabdominal infections. Arch Surg 1997; 132: 1294-1302.
27. Dupont H, Carbon C, Carlet J. Monotherapy with a broad-spectrum beta-lactam is as effective as its combination with an aminoglycoside in the treatment of severe, generalized peritonitis: a multicenter randomized controlled trial. Antimicrob Agents Chemother 2000; 44: 2028-2033.
28. Solomkin J, Yellin A, Rotstein O, Christou NV, Dellinger EP, Tellado JM, et al. Ertapenem versus piperacillin/tazobactam in the treatment of complicated intraabdominal infections: results of a double-blind, randomized comparative phase III trial. Ann Surg 2003; 237: 235-245.
29. Goldstein JC, Snydman DR. Intra-abdominal infections: review of the bacteriology, antimicrobial susceptibility and the role of ertapenem in their therapy. J Antimicrob Chemother 2004; 53 (Suppl. 2):ii29-36.